Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diethylamino hydroxybenzoyl hexyl benzoate is an organic compound used as a UV filter in sunscreens and cosmetic products. It absorbs ultraviolet A (UVA) radiation, with peak absorption at 354 nm, thereby protecting the skin from acute and chronic photodamage caused by UVA exposure. The compound is oil-soluble and can be incorporated into the oil phase of emulsions. It exhibits good photostability compared to other UVA filters such as avobenzone. In addition to its UV filtering properties, in vitro studies have shown that it has anti-inflammatory effects by inhibiting edema formation in inflammation models. Diethylamino hydroxybenzoyl hexyl benzoate was approved for use in Europe in 2005 and is also marketed in the United States, South America, Mexico, Japan, and Taiwan[1][2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diethylamino hydroxybenzoyl hexyl benzoate.